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Abstract Gemcitabine is a fluorine-substituted cytara- 
bine analog with broad experimental antitumor activ­
ity. It’s activity was explored in chemotherapy-naive 
patients with advanced progressive renal-cell carci­
noma. A total of 39 patients were included in the study, 
of whom 37 were fully evaluable. In five patients the 
primary tumor remained in situ. Gemcitabine at 
800 mg/m2 was given as a weekly 30-min infusion for 
3 consecutive weeks followed by 1 week of rest. One 
complete response and two partial responses were ob­
served giving a response rate of 8.1% [95% confidence 
interval (Cl), 2-22%). The duration of the responses is 
currently 32, 15, and 19 months, respectively. The me­
dian survival for all patients was 12.3 months. Gem­
citabine was generally well tolerated, with nausea and 
vomiting (20.5% grade III) and neutropenia (5.3% 
grade III) being the most significant side effects. Gem­
citabine given at this dose level and on this schedule has 
only limited activity in advanced renal-cell carcinoma.
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Introduction
Patients with renal-cell carcinoma (RCC) currently 
have few therapeutic options once metastatic disease 
has developed. Approximately 25% of the patients 
have metastatic disease at the time of first presentation 
[1]. The median survival for these patients is 6-12 
months, independent of treatment [2]. Spontaneous 
regression of metastases after tumor nephrectomy oc­
curs in less than 1%) of cases [3]. Treatment with 
hormones has no proven impact on survival [4, 5]. The 
results of chemotherapy have been consistently disap­
pointing, with most studies revealing response rates 
below 10%. Agents with some activity are vinblastine 
and floxuridine. One of the explanations for this rela­
tive chemotherapy insensitivity is the high level of 
expression of the multi drug resistance gene in the 
proximal tubular cell, known to be the origin of re­
nal-cell carcinoma. Several forms of immunotherapy 
with interferons and interleukin-2 have been applied, 
resulting in a limited number of sometimes durable 
responses [6, 7]. Further studies with new agents are 
therefore indicated,
Gemcitabine (2'2-difluorodeoxcytidine), a pyrimid­
ine antimetabolite, has been developed as a new de- 
oxycytidine analogue. In several murine solid-tumor 
and human xenograft models, gemcitabine has been 
identified as an active compound with a very broad 
therapeutic index. The dose-limiting side effects in 
phase I studies were myelosuppression and, for a more 
frequent, daily-times-5 regimen, a flu-like syndrome 
consisting of fever, malaise, headache, and rigors; in 
rare cases, hypotension was observed. The regimen 
chosen for further exploration in the phase II setting 
was weekly administration times 3 every 4 weeks. In 
this paper we report on the results we obtained in 
a multicenter phase II study in advanced progressive 
RCC.
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Patients and methods
This was an open, nonrandomized study to determine the objective 
response rate to gemcitabine of patients with advanced RCC who 
had not had previous chemotherapy. The study was conducted from 
three centers in Germany and one in The Netherlands. The prin­
ciples of good clinical practice and the Declaration of Helsinki were 
adhered to and the protocol was approved by the local ethics 
committees. Informed consent was obtained from all patients before 
their inclusion in the study.
Criteria for entry
To be included in the study, patients (aged 18-75 years) had to have 
histologically or cytologically confirmed metastatic or inoperable 
advanced renal cell adenocarcinoma. They had to have a life expect­
ancy of at least 3 months and a performance status of 0-2 on the 
WHO scale. Nephrectomy was permitted, but this had to have been 
at least 3 weeks before the start of the study together with documen­
tation of disease progression. If an area had been irradiated, there 
had to be measurable disease outside this area. Palliative 
radiotherapy was allowed in areas outside the axial skeleton. There 
had to be adequate bone marrow reserve (leukocytes, > 4 x 109/1; 
hemoglobin, lOg/dl [6.7 mmol/1], platelets, ^  100 x 109/1). The fol­
lowing laboratory criteria had to be fulfilled: plasma creatinine levels 
of < 160 mmol/I, plasma bilirubin concentrations lower than twice 
the normal value, and aspartate transaminase/alanine transferase 
(AST/ALT) levels lower than 3 times the normal value. AST and 
ALT could be elevated to 5 times the normal value in patients with 
known metastatic disease in the liver. The prothrombin time (PT) 
and partial thromboplastin time (PTT) had to be < 1 .5  times the 
normal value.
Patients were excluded from the study if they had any of the 
following: bilateral renal cancer, bony lesions as the only measurable 
disease, life-threatening metastases, or a second malignancy (except 
for in situ carcinoma of the cervix or adequately treated basal-cell 
carcinoma of the skin). Further exclusion criteria were central ner­
vous system involvement, hypercalcemia ( >  10.5 mg/dl), active un­
controlled infection, or any serious concomitant systemic disorder 
deemed by the investigator to be incompatible with the study. 
Patients could not have received previous chemotherapy, although 
prior treatment with a biological response modifier was allowed. 
Concomitant hormonal and corticosteroid treatments were not al­
lowed. Men and women had to take medically approved contracept­
ive precautions (if necessary) during the trial and for 3 months after 
receiving the final dose of study drug. Finally, patients who could 
not be adequately followed for the duration of the study were 
excluded.
Treatment
Gemcitabine at 800 mg/m2 was given intravenously (infusion period, 
30 min) once a week for a consecutive 3-week period, which was 
followed by 1 week of rest, this constituting a cycle of 28 days. 
Patients who completed one cycle of therapy at 800 mg/m2 could 
have the subsequent dose increased by up to 20%, provided that 
they had shown no significant change from baseline in hematologi­
cal parameters and that nonhematological toxicity had not been 
more severe than WHO grade 1, If the patient tolerated this escala­
tion for the whole cycle, subsequent cycles conld be given in dose 
escalations of up to 20% to a maximum of 1200 mg/m2. Dose 
adjustments were made on the basis of assessments of hematological 
and non-hematological toxicities. Only 50% of a dose was given if 
the WBC was >  2.0 but < 3,0 x 109/1 or the platelet count was 
50-99 x 109/1. If the cell counts dropped below the lower level of
either range, the injection was omitted. Patients with a grade 3 non­
hematological toxicity could either have their dose reduced by 50% 
or have therapy withheld, depending on the judgement of the investi­
gator. Patients with a life-threatening grade 4 non-hematological 
toxicity were removed from the study unless they were responding, 
in which case a 50% dose reduction could be instituted when the 
toxicity resolved.
Evaluation of response and toxicity
All patients who completed one cycle of therapy (including those 
withdrawn within this period for toxicity) qualified to be analyzed 
for efficacy, and all patients who were enrolled in the study were 
analyzed for safety. Efficacy was examined in each patient before 
each therapy cycle, i.e., every 4 weeks (medical history and physical 
examination, performance status evaluation, analgesics use), and 
before every other therapy cycle, i.e., every 8 weeks [chest X-ray, 
computerized tomography (CT) scan if appropriate, radiological 
tests]. Patients were then reviewed at 1 month after the last dose of 
study drug for assessment of efficacy and every 3 months for evalu­
ation of survival and disease-free survival.
All responders were evaluated by a panel of independent experts, 
the Oncology Review Board (ORB). The evaluations were conduc­
ted using standard WHO criteria for measurable disease, duration of 
response, and survival. Efficacy data-analysis methods included de­
termination of the tumor response rate and calculation of the 95% 
confidence intervals (CIs). Data for supportive response parameters 
such as performance status, weight, and analgesics consumption and 
for other disease-related symptoms reflecting either patients benefit 
or their clinical condition were also collected prospectively for all 
patients. Improvement had to be maintained for at least 4 weeks to 
be considered clinically relevant.
Results
Between February 1990 and July 1991, 39 patients (29 
men and 10 women) were enrolled in the study. All 
received at least 1 dose of gemcitabine, and 37 were 
eligible for evaluation of efficacy. The disease charac­
teristics at baseline are shown in Table 1. The median 
interval from diagnosis of the tumor to entry into the 
study was 12.6 months (range, 0-92.5 months). Of the 
37 qualified patients, 43.2% had undergone previous 
surgery in an attempt at curative resection and 13.5% 
were receiving analgesics.
Efficacy
Of the 39 patients enrolled, 18 withdrew from the study 
due to lack of efficacy. Three patients were confirmed by 
the ORB as being responders to treatment with gem­
citabine, giving a response rate of 8.1% (95% Cl, 
1.7-21.9%). One patient experienced a complete re­
sponse (CR). This was a 51-year-old man with a local 
recurrence after previous nephrectomy, who experienced 
a partial response (PR) after two cycles and a CR after 
four cycles. Disease progression has not been reported to 
date (32 months after the start of treatment).
Two patients achieved a PR. One was a 47-year-old 
man who entered the study at 36.5 months following
493
Tabic 1 Summary of patients and disease characteristics at base­
line
Eligible Patients 37
M/F 29/8
Age (years):
Mean ±  SD 
Range
Site of disease:
Lung
Lymph node 
Bone 
Liver 
Kidney 
Other
Prior therapy:
Any surgery 
Radiotherapy 
Immunotherapy
Performance status:
0 
1 
2 
3
Level of analgesia:
0 
1 
2 
3
Number of sites (n =  39):
1 20(51.2%)
2 10 (25.6%)
3 7(17.9%) 
> 3  2(5.1%)
a nephrectomy for the primary tumor, when a CT scan 
revealed recurrent disease in a retrocrural lymph node. 
A PR was seen after two cycles, and the patient was 
withdrawn from the study after three cycles at his own 
request. At disease progression (after 12 months), he 
was treated further with gemcitabine (five cycles) and 
again achieved a PR after two cycles, but his disease 
progressed in the retrocrural nodes thereafter and 
treatment was discontinued. The second patient who 
showed a PR was a 57-year-old man. He was pre­
treated with alpha- and gamma-interferon. On entering 
the study, he showed 13 measurable lung metastases. 
After ten cycles a PR was noted with concomitant 
improvement of his performance status. He received 
a total of 16 cycles. At 9 months after discontinuation, 
clear progression was documented. Gemcitabine treat­
ment was restarted and continued for a total of 16 
months, resulting in disease stabilization. In all, this 
patient has received up to 100 gemcitabine infusions. 
His survival from the start of treatment is currently 48 
months.
A third case reported by the investigator as a PR was 
not confirmed by the ORB. The radiology was difficult
to interpret, bu t it was thought that the patient had 
a mixed response, with some lesions responding while 
others progressed. The patient clearly progressed both 
locally and in his lung after five cycles, and this resulted 
in study termination.
The median time to disease progression after the 
study was 3.7 months; the minimum was 0.7 months 
and the maximum was 33.9 months at the data cutoff 
date. Six patients had not declared disease progression. 
The median overall survival was 12.3 months; the min­
imum was 0.7 months and the maximum was 33.9 
months at the data cutoff date. In all, 13 patients were 
not reported to have died.
Disease progression data were available for 31 quali­
fied patients and, as at baseline, were typical for 
patients with renal carcinoma. The m ajor site of meta­
static failure was the lung in 23 patients, the lymph 
nodes in 4 patients, and the brain in 3 patients, with 
a wide distribution of disease progression occurring at 
other anatomical sites. There was no meaningful im­
provement in any of the secondary efficacy parameters 
assessed.
Safety
Dose administration
During this study, a total of 39 patients received at least
1 dose of gemcitabine. A mean of 3.7 (range 0-16) cycles 
were completed. Gemcitabine was generally well toler­
ated, with only 1.6% of all injections being omitted and 
only 12.8% being reduced in dose. Hematological 
toxicity accounted for four dose omissions; diarrhea, 
for three omissions; and edema, for one omission. One 
further omission occurred when the patient failed to 
attend the clinic. Most dose reductions (70%) occurred 
during the first three cycles, usually as a result of 
leukopenia (83% of all dose reductions). In  addition, 
4.6% of injections were escalated above the protocol- 
defined starting dose.
W H O  laboratory toxicity
WHO laboratory toxicities are reported in Table 2 
as the maximal toxicity experienced by the patient. 
The overall tolerance of gemcitabine was good. 
There was no W HO grade 4 toxicity, and grade 3 
toxicity for anemia, leukopenia, and thrombocytopenia 
were reported in only 13.2%, 5.3%, and 7.9% of 
patients, respectively. Although disturbances in hep­
atic enzymes were commonly found, these were mostly 
mild (only one patient had grade 3 toxicity) and of 
little clinical significance, When the data were analyzed 
according to therapy cycle, there appeared to be no 
trend toward increased toxicity as multiple cycles were 
given.
56.62 ±9.31 
38-74
30 (81.1%) 
15(40.5%) 
7 (18.9%)
4 (10.8%)
5 (13.5%) 
15(40,5%)
34 (91.9%) 
5 (13.5%) 
20 (54.1%)
15(40.5%) 
19(51.4%) 
2 (5,4%)
1 (2.7%)
32 (86.5%) 
3 (8.1%)
1 (2.7%)
1 (2.7%)
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Table 2 WHO grades for
laboratory and clinical toxicity Toxicity parameter 
(% of patients, all 39 patients)“ (laboratory)
Alkaline phosphatase 
Alkaline transaminase 
Aspartate Transaminase 
Bilirubin
Blood urea nitrogen
Creatinine
Hemoglobin
Hematuria
White blood cells
Segmented neutrophils1
Platelets
Proteinuria
Number of 
patients with
data 0 1 2 3 4
38 71.1 18.4 7.9 2.6 0
38 36.8 50.0 5.3 7.9 0
38 63.2 28.9 2.6 5.3 0
36 97.1 8.3 0 0 0
38 73.7 21.1 5.3 0 0
38 57.9 42.1 0 0 0
38 28.9 31.6 26.3 13.2 0
37 54.1 27.0 16.2 2.7 0
38 26.3 34.2 34.2 5.3 0
38 31.6 21.1 28.9 15.8 2.6
38 76.3 7.9 7.9 7.9 0
38 44.7 47,4 7.9 0 0
Toxicity parameter clinical) 0 1 2 3 4
Allergic 92.3 7.7
Cutaneous 71.8 20.5 7.7
Fever 64.1 17.9 17.9
Cardiac function 92.3 2.6 2.6 2.6
Hair 89.7 5.1 5.1
Infection 89.7 7.7 2.6
Nausea/vomiting 38.5 28.2 12.8 20.5
Pain 87.2 7.7 5,1
Peripheral neurotoxicity 92,3 7.7
Pulmonary 92.3 5.1 2.6
ilMaximal recorded WHO grade
bSegmented neutrophil counts have been coverted to WHO scores using granulocyte count criteria
W H O  clinical toxicity
The clinical toxicity is summarized in Table 2. There 
was one grade 4 toxicity: cardiac function. This patient 
had a history of cardiac disease, including a myocardial 
infarction, and died of heart failure and arrhythmia, 
which was not thought to be drug-related. A second 
patient developed pneumonia after two injections of 
gemcitabine and rapidly deteriorated and died* The 
pneumonia was thought to be both disease- and drug- 
related by the investigator, but there was no concomi­
tant leukopenia.
As expected, nausea and vomiting were the most 
common adverse events encountered, with only 38.5% 
of patients remaining unaffected. Grade 1 toxicity 
(nausea) was reported by 28.2% of patients: grade
2 toxicity (transient vomiting), by 12.8%; and grade
3 toxicity (vomiting requiring therapy), by 20.5%. 
However, no grade 4 toxicity (intractable vomiting) was 
reported. Other frequently reported adverse events in­
cluded fever (35.9%), asthenia (35.9%), flu-like syn­
drome (17.9%), and skin rash (17.9%). Grade 3 toxicity 
was reported by two patients, one with dyspnea and 
one with a myocardial infarction.
The occurrence of alopecia was minimal. There was 
no grade 3 or 4 toxicity, and 89.7% of patients reported 
no hair loss at all. The majority of patients reported no 
pain during the study (87.2%).
Seven patients were withdrawn due to the following 
adverse events experienced during the study irrespect­
ive of drug causality: persistent pretibial edema (one 
patient); worsening exanthema (one patient); severe 
nausea and vomiting (one patient); asthenia, pain, 
nausea, and vomiting (one patient); myocardial infarc­
tion (one patient); and thrombocytopenia (one patient).
Discussion
In view of the overall response rate of 8.1%, gem­
citabine monotherapy delivered at a dose of 800 mg/m2 
weekly for 3 weeks followed by 1 week of rest should
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not be considered active in advanced renal-cell carci­
noma when used at the tested dose and regimen. The 
population studied had a WHO performance status of 
0 or 1 in 91.9% of cases, and the majority had pulmon­
ary and nodal disease. Therefore, the present cohort is 
a reflection of the type of patient entered in study 
protocols with biological response modifiers, the excep­
tion being that five patients had their primary tumor in 
situ.
The responses observed were of good quality, and 
the appearance of a response in our third patient after 
ten cycles was remarkable. This patient never pro­
gressed during treatment, and after the restart of gem­
citabine, disease stabilization occurred but no regres­
sion was observed, suggesting more of a cytostatic than 
a cytotoxic effect in this particular patient. The median 
survival of 12.3 months compares favorably with that 
obtained in many other studies but is probably more 
a reflection of the patient population than a result of 
therapy.
The toxicity of gemcitabine was fairly acceptable, 
with nausea and vomiting being the most prominent 
feature. It is unclear whether the newly available 5- 
hydroxytryptamine3 antagonist might prevent this side 
effect, as it was not routinely applied in the present 
study. Bone marrow toxicity was generally mild, and 
there was no incidence of neutropenic fever. In one 
patient, grade IV granulocytopenia was seen, A more 
recently completed phase I study revealed a maximal 
tolerated dose (MTD) of 1250 mg/m2 per week given 
for 3 weeks followed by 1 week of rest in nonpretreated 
patients [8]. A review of 201 chemotherapy-naive pa­
tients treated at the same dose showed the occurrence 
of grade III neutropenia in 23% of the patients and of 
grade IV neutropenia in 6% [9], In our study, only in 
4.6% of the injections was the dose escalated, on the 
other hand, only 12.8% involved dose reductions due
to bone marrow toxicity. It is unclear whether a dose- 
response relationship exists for gemcitabine in renal­
cell cancer. In view of the phase I data presented thus 
far, a further dose escalation might be possible. The 
results of our study are in agreement with those ob­
tained in an earlier reported, smaller phase II study 
applying the same dose and regimen, where only one 
PR was noted [10].
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